There are 2137 resources available
1041P - Explore the efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients of different gender
Presenter: Shu-yue Zheng
Session: E-Poster Display
Resources:
Abstract
1043P - A review of meta-analyses on the impact of antibiotics on the efficacy of immune checkpoint inhibitors and cancer patients’ survival
Presenter: Julie Cervesi
Session: E-Poster Display
Resources:
Abstract
1044P - Predicting response to checkpoint inhibitors using complex molecular characteristic and immunoprofiling in solid tumours
Presenter: Simona Borilova
Session: E-Poster Display
Resources:
Abstract
1045P - The prognostic value of derived neutrophil-to-lymphocyte ratio in patients treated with checkpoint inhibitors
Presenter: William Mullally
Session: E-Poster Display
Resources:
Abstract
1046P - Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials
Presenter: Chun Loo Gan
Session: E-Poster Display
Resources:
Abstract
1047P - Long terms efficacy of anti-PD(L)1 in MSI tumours
Presenter: Cristina Smolenschi
Session: E-Poster Display
Resources:
Abstract
1048P - Should I stay or should I go: Optimal duration for antiPD(L)1 therapy
Presenter: Jeanne Chen
Session: E-Poster Display
Resources:
Abstract
1049P - Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
Presenter: Amit Kumar
Session: E-Poster Display
Resources:
Abstract
1050P - Does immunotherapy impact the outcomes of future anti-tumour therapies?
Presenter: Manuela Tiako Meyo
Session: E-Poster Display
Resources:
Abstract
1051P - Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease
Presenter: Sarah Nikiforow
Session: E-Poster Display
Resources:
Abstract